ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

Home 9 Uncategorized 9 ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)